Mechanisms and Medical Countermeasures for Ultra-Potent Synthetic Opioid Overdose - PROJECT SUMMARY Ultra-potent synthetic (UPS) opioids such as fentanyl and the emerging nitazenes represent escalating public-health and national-security threats. Fentanyl now dominates overdose deaths worldwide and has been used in mass-casualty incidents involving aerosolized fentanyl derivatives, while nitazenes – distinct benzimidazole opioids with even greater potency – are increasingly detected in the illicit drug supply. Both drug classes cause profound respiratory depression and “wooden-chest” rigidity, yet fentanyl can also produce lethal vocal-cord closure (VCC) and rapid cardiovascular collapse. These effects are minimally reversible with naloxone, particularly when administration is delayed or given intramuscularly, suggesting additional non-μ- opioid receptor (MOR) mechanisms. Etonitazene, a prototypical nitazene, likewise produces VCC and death but at doses ~10-fold lower than fentanyl, indicating an even greater propensity for airway obstruction and potentially for other physiologic toxicity. Moreover, clonidine, an α₂-adrenergic receptor (α₂-AR) agonist, restores respiration and airway patency after fentanyl when combined with naloxone, whereas either drug alone fails. Also, another α₂-AR agonist, dexmedetomidine, restores respiration and airway patency after etonitazene when combined with naloxone, whereas naloxone alone fails. These results, in combination with in vitro studies that demonstrate that fentanyl, carfentanil, and several nitazenes display micromolar affinity and antagonism at α₂-ARs, imply interference with brainstem noradrenergic regulation of airway and cardiovascular function. This project will systematically define the physiological and pharmacological mechanisms underlying nitazene and fentanyl analogue toxicity and evaluate α₂-AR and MOR-targeted countermeasures in a validated rat model that replicates UPS opioid-induced airway and cardiovascular collapse. Animals will receive intravenous UPS opioids, followed by intravenous or intramuscular rescue treatments (naloxone, nalmefene, clonidine, or related α₂-agonists) at clinically relevant delays (15 and 45 seconds). Experiments will establish ED₅₀/ED₁₀₀ thresholds, examine the limits of naloxone efficacy, test the role of noradrenergic neurons in mediating toxicity, and determine how MOR and α₂-AR modulation affect rescue success. By defining both MOR-dependent and noncanonical adrenergic mechanisms of UPS toxicity, this work will provide a mechanistic foundation for novel, field-deployable countermeasures. The findings will directly inform emergency medical response, overdose prevention strategies, and national preparedness for chemical- threat scenarios involving UPS opioids.
